Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats

Cardiovascular Research

Volumn 79, Issue 2, 2008, Pages 322-330

  Soliman, Hesham ^a   Craig, Graham P ^a   Nagareddy, Prabhakar ^a   Yuen, Violet G ^a   Lin, Guorong ^a   Kumar, Ujendra ^a   McNeill, John H ^a   MacLeod, Kathleen M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Contractility; Diabetic cardiomyopathy; iNOS; Rho kinase; RhoA

Indexed keywords

EZRIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIM PROTEIN; LIPOPOLYSACCHARIDE; MOESIN; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; RADIXIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVATION; HEART CELL CULTURE; HEART MUSCLE CONTRACTILITY; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; LIPOPOLYSACCHARIDES; LYSINE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; NITROPRUSSIDE; RATS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; STREPTOZOCIN;

EID: 46749101728     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn095     Document Type: Article

References (33)

1. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes. Part I: general concepts. Circulation 2002;105:1727-1733.
2. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes. Part II: potential mechanisms. Circulation 2002;105:1861-1870.
3. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-334.
4. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290:C661- C668.
5. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 2006;27:97-104.
6. Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 2007;75:51-58.
7. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
8. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003;278:9472-9480.
9. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol 2005;289:H2144-H2152.
10. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
11. Ferrini MG, Davila HH, Valente EG, Gonzalez-Cadavid NF, Rajfer J. Aging-related induction of inducible nitric oxide synthase is vasculoprotective to the arterial media. Cardiovasc Res 2004;61:796-805.
12. Lee CC, Lee YY, Chang CK, Lin MT. Selective inhibition of inducible nitric oxide synthase attenuates renal ischemia and damage in experimental heatstroke. J Pharmacol Sci 2005;99:68-76.
13. Madonna R, Di Napoli P, Massaro M, Grilli A, Felaco M, De Caterina A et al. Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005;280:13503-13511.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
15. Chitaley K, Weber D, Webb RC. RhoA/Rho-kinase, vascular changes, and hypertension. Curr Hypertens Rep 2001;3:139-144.
16. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 2001;51:169-177.
17. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002;55:757-767.
18. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37:3886-3888.
19. Gronholm T, Cheng ZJ, Palojoki E, Eriksson A, Backlund T, Vuolteenaho O et al. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. Eur J Pharmacol 2005;519:267-276.
20. Sauzeau V, Rolli-Derkinderen M, Lehoux S, Loirand G, Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 2003;93:630-637.
21. Rolli-Derkinderen M, Sauzeau V, Boyer L, Lemichez E, Baron C, Henrion D et al. Phosphorylation of serine 188 protects RhoA from ubiquitin/ proteasome-mediated degradation in vascular smooth muscle cells. Circ Res 2005;96:1152-1160.
22. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem 2003;278:19023- 19031.
23. Chitaley K, Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 2002;39:438-442.
24. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/ Rho-kinase signaling to cause penile erection. Eur J Pharmacol 2002;439:173-174.
25. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000;275:21722-21729.
26. Sandu OA, Ito M, Begum N. Selected contribution: insulin utilizes NO/ cGMP pathway to activate myosin phosphatase via Rho inhibition in vascular smooth muscle. J Appl Physiol 2001;91:1475-1482.
27. Begum N, Sandu OA, Duddy N. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways. Diabetes 2002;51:2256-2263.
28. Loirand G, Guilluy C, Pacaud P. Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med 2006;16:199-204.
29. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007;262:173-183.
30. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007;4:84-88.
31. Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005;25:1617-1622.
32. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb. Exp. Pharmacol. 2006;166 (Pt1):213-254.
33. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 1995;34:215-234.